The burden of RSV is highest in the very young. Dr. Sehulong Robert Moraba participated in a major international effort to address this as a Sub-Investigator for the Phase 3 PEARL trial (VAD00004). This was a large, multinational, observer-blind, placebo-controlled study to evaluate the efficacy and safety of Sanofi’s RSV vaccine in infants and toddlers.
This critical trial (SAHPRA ref: 20240606) aimed to provide direct protection to children during their most vulnerable early years. Dr. Moraba’s role at Setshaba Research Centre contributed South African data to this global study, ensuring local disease patterns and populations were represented in the results.
